---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108082"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:10.568401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aardvark Therapeutics Q2 net loss $14.4M; advances ARD-201 obesity trials and expands PWS trial to younger patients

## Summary
- Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.
- Cash, cash equivalents, and short-term investments of $141.8M as of June 30, 2025; funds operations into 2027.
- Preclinical data shows ARD-201 prevents weight regain after GLP-1RA discontinuation; Phase 2 POWER trial in H2 2025, STRENGTH in H1 2026.
- Phase 3 HERO trial for ARD-101 in PWS to expand to patients under 13; topline data expected Q3 2026.
- Appointed new CSO, CCO, SVP Regulatory, and General Counsel in May 2025.

## SEC filing metadata
- accession: 0000950170-25-108082
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/0000950170-25-108082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/ck0001774857-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108082
- JSON: https://secwatch.observer/filing/0000950170-25-108082.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.